Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
Qurient Announces Collaboration Agreement With MSD To Evaluate Selective CDK7 Inhibitor Q901 In Combination With KEYTRUDA
https://www.businesswire.com/news/home/20220914005974/en/